Abstract Library

#1219 Changes in Neuroendocrine Tumor Microenvironment with WHO Tumor Grading

Introduction: The microenvironment of neuroendocrine neoplasias (NEN) in view of tumor grading (WHO classification of 2000 und 2010) has not yet been validated. Both classifications distinguish between well and poorly differentiated neuroendocrine tumors, including proliferation rate, mitotic index and histomorphology. The WHO classification of 2000 further evaluates tumor location, size, angioinvasion, invasion of the muscle layer, functionally active tumors and metastases.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cameron S

Authors: Cameron S, Skupin J, Füzesi L,

Keywords: NEN stroma,

#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors

Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Holt N, Villadsen G, Olesen R, Grønbæk H,

Keywords: poorly differentiated neuroendocrine tumors, PDEC, survival,

#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.

Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Deutschbein T, Unger N, Yuece A, Lahner H, Mann K,

Keywords: efficacy, cytotoxic agents, ,